Article Category: Review
Publicado en línea: 23 abr 2016
Páginas: 129 - 138
Recibido: 30 jun 2014
Aceptado: 29 sept 2014
DOI: https://doi.org/10.1515/raon-2015-0003
© 2016 Radiol Oncol
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Malignant (high-grade) gliomas are rapidly progressive brain tumors comprising of anaplastic oligodendroglioma, anaplastic astrocytoma, mixed anaplastic oligoastrocytoma (all grade III, World Health Organization [WHO]) and glioblastoma (grade IV, WHO).1
The incidence of malignant gliomas is approximately 5/100,000. Malignant gliomas constitute 35–45% of primary brain tumors. Glioblastomas account for approximately 60 to 70% of malignant gliomas, while anaplastic astrocytomas represent 10 to 15%, and anaplastic oligodendrogliomas and anaplastic oligoastrocytomas 10% of malignant gliomas.1-3 The incidence of these tumors has increased slightly over past two decades, especially in the elderly. The peak incidence is in the fifth and sixth decade of life. The median age of patients at the time of diagnosis in the case of glioblastoma is 64 years and in the case of anaplastic gliomas 45 years. Malignant gliomas are 40% more frequent in men than in women and twice more frequent in white population than in black one.2,4,5
In Slovenia from 1991 till 2005, a total of 1636 patients (878 males and 758 females) were diagnosed with brain cancer. Since 2001 till 2005 the microscopical verification was performed in 83% of cases: 82% were gliomas, of which two thirds were glioblastoma, 14% astrocytoma and 10% oligodendroglioma. Approximately 60% of the patients were diagnosed at age between 50 to 74 years, and 25% at age between 20 to 49 years.6
The only established environmental risk factor identified for the majority of malignant gliomas is exposure to ionizing radiation.4 There is suggestive evidence with unclear importance of and association of immunologic factors in the development of malignant gliomas, as patients with atopy have a reduced risk of gliomas7 and patients with glioblastoma with elevated IgE levels appear to live longer than those with normal levels.8 Also gene polymorphisms that affect detoxification, DNA repair, and cell cycle regulation have also been implicated in the development of gliomas.4
Few genetic syndromes are associated with the increased risk for malignant gliomas.9 Five percent of patients with malignant gliomas have a family history of gliomas, such as neurofibromatosis 1 and 2, retinoblastoma, the Li-Fraumeni syndrome, the Turcot’s syndrome (the inherited mutations are presented in the Table 1).10
Inherited mutation present in patients with malignant gliomas
| Syndrome | Gene name | Chromosomal location |
|---|---|---|
| Neurofibromatosis 1 | Neurofibromin 1 (NF1) | 17q11 |
| Neurofibromatosis 2 | Neurofibromin 2 (NF2) | 22q12 |
| Tuberous sclerosis | Tuberous sclerosis 1 (TSC1) Tuberous sclerosis 2 (TSC2) | 9q34 16p13 |
| Retinoblastoma | Retinoblastoma 1 (RB1) | 13q14 |
| Li-Fraumeni syndrome | Tumor suppressor p53 (TP53) | 17p13 |
| Turcot's syndrome and multiple hamartoma | Adenomatous polyposis coli (APC) DNA mismatch repair genes: Recombinant human MutL homolog-1 (hMLH2) MutS homolog 2 (hMSH2) Mismatch repair endonuclease (PMS2) Phosphatase and tensin homolog (PTEN) | 5q21 3p21.3 2p22-21 7p22 10q23.3 |
The malignant gliomas arise from neural progenitor cells. Malignant gliomas contain multipotent tumour stem cells that are responsible for populating and repopulating the tumours.11,12
Classical cytogenetic and array – based comparative genomic hybridization studies of gliomas have identified copy number changes (deletions, amplification, gains) in several regions; deletions and loss of heterozygosity in tumours might point to genes involved in tumour initiation or progression (e.g. oncogenes). The chromosomal alterations that are mostly observed in gliomas are presented in Table 2.10
The chromosomal alterations, mostly observed in gliomas
| Chromosomal region | Type of alteration | Candidate gliomas genes |
|---|---|---|
| 1p36.31-pter | Gains and deletions | Not known |
| 1p36.22-p36.31 | Gains and deletions | Not known |
| 1p34.2-p36.1 | Gains and deletions | Not known |
| 1q32 | Gains | Receptor interacting protein kinase 5 (RIPK5), mouse double minute 4 (MDM4), phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta (PIK3C2B) and others |
| 4q | Deletions | NIMA-related kinase 1 (NEK1), NIMA |
| 7p11.2-p12 | Amplifications or gains | |
| 9p21-p24 | Deletions | Cyclin-dependent kinase inhibitor 2A (CDKN2) |
| 10q23 | Deletions | Phosphatase and tensin homolog (PTEN) |
| 10q25-q26 | Deletions | O-6-methylguanine-DNA methyltransferase (MGMT) |
| 11p | Deletions | Between cyclin-dependent kinase inhibitor 1C (CDKN1C) and related RAS viral (r-ras) oncogene homolog 2 (RRAS2) |
| 12q13.3-q15 | Amplifications | Mouse double minute 2 homolog (MDM2), cyclin-dependent kinase 4 (CDK4) and others |
| 13p11-p13 and 13q14-q34 | Loss | Retinoblastoma 1 (RB1) |
| 19q13 | Loss | Glioma tumor suppressor candidate region gene 1 (GLTSCR1), GLTSCR2, ligase I, DNA, ATP-dependent (LIG1), cytohesin 2 (CYTH2) and many others |
| 22q11.21-q12.2 | Loss | 28 genes, including integrase interactor 1 (INI1) |
| 22q13.1-q13.3 | Loss | Not known |
The transition from low grade to anaplastic astrocytoma is associated with inactivation of tumour suppressor genes on chromosomes 9p, 12q and 19q. Loss of chromosome 13q, which includes the retinoblastoma (RB) gene focus, occurs in approximately 30% of higher-grade astrocytic tumours. Two-thirds of malignant astrocytomas and glioblastomas have homozygous deletions of the region of chromosome 9p that includes the cyclin-dependent kinase inhibitor 2A (CDKN2A) and CDKN2B genes. In general, RB, CDKN2A and cyclin- dependent kinase (CDK)4 gene alterations are mutually exclusive in glioblastomas.13 Malignant progression to glioblastoma is also associated with inactivation of the phosphatase and tensin homolog (PTEN) tumour suppressor gene on chromosome 10 and amplification of the epidermal growth factor receptor (EGFR) gene.14 The loss of chromosome 10 occurs in 60% to 85% of glioblastomas, with approximately 25% of cases having PTEN mutation.15 In approximately 40% of glioblastomas the EGFR gene is amplified, resulting in overexpression of EGFR.16
Glioblastomas can be classified as primary or de novo and secondary or progressive. Primary glioblastomas comprises the majority of cases (60%), develop in older patients (> 50y), without prior clinical history of less malignant tumours, presenting after the short medical history (less than 6 months). Secondary or progressive glioblastomas (40%) are common among younger people (< 45y) and arise through the progression from lower-grade astrocytomas (WHO grade II) or anaplastic astrocytomas (WHO grade III), with varying time for the progression, between less than 1 year to more than 10 years. Primary and secondary glioblastomas obviously constitute distinct disease entities that evolve through different genetic pathways. CDKN2A deletions, PTEN alterations and EGFR amplification are more prevalent among de novo glioblastomas and less frequently, mouse double minute 2 homolog (MDM2) amplification, whereas p53 mutations develop as earliest detectable alteration in secondary glioblastomas (Figure 1).17
Development of primary and secondary glioblastoma
DCC = deleted in colon cancer gene; LOH = loss of heterozygosity; PDGF = platelet-derived growth factor; PDGFR = platelet-derived growth factor receptor; RB = retinoblastoma gene
Magnetic resonance imaging (MRI) in recurrent g lioblastoma patient, treated at Institute of Oncology Ljubljana, with bevacizumab/irinotecan, (A) before and (B) after six months of treatment.
Age, tumour grade (anaplastic gliomas
Also for patients with newly diagnosed glioblastoma, nomograms that incorporate patient age, extent of resection, use of postoperative (adjuvant) temozolomide, mental status and corticosteroid use as a baseline for prognostic factors, have been developed for estimation of the median survival and two year survival probability, as a helpful tool in decision making for individual patients.21 Nomograms have been developed on the bases of Stupp
Oligodendrogliomas with 1p/19q deletions have been recognized as distinct pathologic entities with particular sensitivity to RT and chemotherapy (ChT). In the retrospective analysis, the patients with tumours’ epigenetic silencing of the methyl-guanine methyl transferase (MGMT) gene promoter by methylation benefited from temozolomide. The tumours were unable to repair ChT induced DNA damage.23
IDH1 (NADP+-dependent isocitrate dehydrogenases) mutation occurs in the vast majority of WHO grade II or III gliomas and secondary glioblastomas.24 The p.Arg132His mutation (substitution of arginine with histidine) of isocitrate dehydrogenase 1 (IDH1R132H) is not only a frequent alteration (> 70%) but also a major prognostic marker in gliomas.25 Patients with IDH1 mutation have a better treatment outcome and a better survival.26
Clinical manifestations of malignant gliomas depend on the localization and size of the tumour. The variety of symptoms may be present, such as headaches and seizures (50‒60%), focal neurologic deficits, confusion, memory loss and personality changes (20%).27
The classic headache suggestive of increased intracranial pressure is most severe in the morning and may be associated with nausea and vomitting.28
Rarely meningeal dissemination may be the first presentation of malignant gliomas as back pain Nausea/vomiting Cognition changes Personality changes Gait imbalance Urinary incontinence Hemiparesis Aphasia Hemineglect Visual field defect Seizures with or without radicular symptoms, mental status changes, cranial nerve palsies, and myelopathy or cauda equina syndrome (Table 3).29,30
Symptoms at presentation of glioblastoma
| Headache |
|---|
| Nausea/vomiting |
| Cognition changes |
| Personality changes |
| Gait imbalance |
| Urinary incontinence |
| Hemiparesis |
| Aphasia |
| Hemineglect |
| Visual field defect |
| Seizures |
Diagnosis and staging are made by imaging of the brain and tumour hystopathologic verification. For imaging the magnetic resonance (MRI) is preferred, but computed tomography may also be used. Additional biopsy or tumour resection follows afterwards.
Imaging studies show heterogeneously enhancing mass with surrounding oedema. Glioblastomas frequently have central areas of necrosis and more extensive peritumoral oedema than in anaplastic gliomas.31
Tissue diagnosis is essential, it can be attended either at the time of surgical resection or by separate procedure named frameless stereotactic biopsy. In the case of frameless stereotactic biopsy, the neurosurgeon is aware of the three dimensional positions of surgical instruments inside the intracranial space during the biopsy, because it is MRI or CT guided.32 The procedure related mortality is 1–2%.33
Positron emission tomography (PET)34 and magnetic resonance spectroscopy (MRS) can be used to identify metabolically active areas of different tumours, and by that increasing the accuracy of stereotactic brain biopsy. PET can be integrated with the use of 18F-labeled fluorodeoxyglucose (FDGPET) or L-[methyl-(11) C]-methionine (MET-PET) increasing the diagnostic sensitivity and specificity. The both image procedures MET-PET and FDGPET correspond with each other.35
Because of their infiltrative nature, malignant gliomas cannot be completely eliminated with surgery. The standard treatment after surgery today for
MGMT promoter methylation was a major prognostic factor for the improved survival and was predictive of benefit from the therapy. For those with MGMT methylation, the two years survival rates were 49% and 24% with combination therapy and RT alone respectively, while for those without MGMT methylation, the two year survival rates were 15% and 2% respectively.
The 5-year overall survival analysis of the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada (NCIC) trial has shown benefit for patients treated with RT and temozolomide compared with only irradiated patients (9.8%
Adjuvant ChT with procarbazine, lomustine (CCNU) and vincristine (PCV regimen) has failed to improve the survival in individual prospective randomized studies, both in grade IV and in grade III tumours. One large meta-analysis has showed that nitrosourea based CTh marginally improves the survival. Namely, individual patient data from 3004 patients enrolled in 12 randomized controlled trials comparing RT alone or with CTh, were included, CTh was associated with a 15% decrease in the risk of death, which translated to a 6% absolute increase in one year survival (from 40% to 46%) and a two month improvement in the median survival.37
There are no randomized trials that have compared temozolomide with a nitrosourea-based combination regimen when given concurrently with RT followed by the adjuvant therapy.
Another chemotherapeutic approach involves the implantation of biodegradable polymers containing carmustine (Gliadel Wafers, MGI Pharma) into the tumour bed after the resection of the tumour. The aim of the treatment with these polymers, which release carmustine gradually over the course of several weeks, is to kill residual tumour cells. In a randomized, placebo-controlled trial that investigated the use of these polymers in patients with newly diagnosed malignant gliomas, the median survival increased from 11.6 months to 13.9 months (p = 0.03).38 This survival advantage was maintained at 2 and 3 years.39
The newest phase III study data, in patients with newly diagnosed patients with glioblastoma, are coming from Radiation Therapy Oncology Group (RTOG) 0825 and Avastin in Glioblastoma (AVAGLIO) studies. In RTOG 0825 study, 637 newly diagnosed patients were randomly assigned to receive either standard ChT-RT (with temozolomide plus bevacizumab (10 mg/kg intravenous [IV], q 2 weeks), or standard ChT-RT plus placebo). The progression-free survival was significantly improved in the bevacizumab arm: 10.7 months vs. 7.3 months for placebo. However, the overall survival was slightly (although not significantly) worse in the bevacizumab arm: 15.7 months vs. 16.1 months for placebo. In addition, patients in the bevacizumab arm had a greater symptom burden and worse neurocognitive functioning, and they scored worse on several measures of health-related quality of life (QOL) than did patients who received only a standard therapy.40
The AVAGLIO trial, which had a study design very similar to that of RTOG 0825 and which involved 921 patients, also showed an improvement in progression-free survival (10.6 months in the bevacizumab arm vs. 6.2 months in the placebo arm) but virtually identical overall survival (16.8 months vs. 16.7 months, respectively). However, the QOL outcome in the bevacizumab arm was more favourable than in RTOG 0850 and time to the initiation of the corticosteroid treatment to manage adverse effects was also significantly longer in the patients who received bevacizumab (a median of 12.3 months
The standard therapy after surgery for
Anaplastic oligodendrogliomas and anaplastic oligoastrocytomas are generally more responsive to therapy than are pure astrocytic tumours.43 Nearly 90% of patients with anaplastic oligodendrogliomas and 20% patients with anaplastic oligoastrocytomas has a co-deletion of chromosomes 1p and 19q, mediated by an unbalanced translocation of 19p to 1q.44 Tumours in patients with the LOH 1p/19q co-deletion are particularly sensitive to CTh with PCV with response rates of up to 100%, as compared with response rates of 23 to 31% among patients without the deletion LOH of 1p/19q.
Two large phase III studies of PCV ChT with RT, as compared with RT alone, in patients with newly diagnosed anaplastic oligodendrogliomas or anaplastic oligoastrocytomas, have been reported. In both studies, the addition of ChT to RT increased the time to tumour progression by 10 to 12 months, but, did not improve the overall survival (median, 3.4 and 4.9 years).45,46 No difference in efficacy was apparent between PCV and temozolomide CTh43, however, studies directly comparing the two regimens have not been performed (Table 4).
Summary of current treatments for malignant gliomas Additional data are from Sathornsumette
| Type of Tumour | Therapy |
|---|---|
| Newly diagnosed tumours | |
| Glioblastoma (WHO grade IV) | Maximal surgical resection, plus radiotherapy, plus concomitant and adjuvant TMZ Radiotherapy is administered at a dose of 60 Gy given in 30 fractions over a period of 6 weeks. ; Adjuvant TMZ = adjuvant temozolomide, beginning 4 weeks after radiotherapy, 150 mg/m2/day on days 1 to 5 of the first 28-day cycle, followed by 200 mg/m2/day on days 1 to 5 of each subsequent 28-day cycle, if the first cycle was well tolerated; Concomitant TMZ = concomitant temozolomide, 75 mg/m2/ day for 42 days with radiotherapy; PCV = lomustine (CCNU), 110 mg/m2, on day 1; procarbazine, 60 mg/m2 on days 8 to 21; vincristine, 1,5 mg/m2 (maximum dose, 2 mg), on days 8 and 29; WHO = World Health Organization |
| Anaplastic astrocytoma (WHO grade III) | Maximal surgical resection, with the following options after surgery (no accepted standard treatment): radiotherapy, plus concomitant and adjuvant TMZ or adjuvant TMZ alone Radiotherapy is administered at a dose of 60 Gy given in 30 fractions over a period of 6 weeks. ; Adjuvant TMZ = adjuvant temozolomide, beginning 4 weeks after radiotherapy, 150 mg/m2/day on days 1 to 5 of the first 28-day cycle, followed by 200 mg/m2/day on days 1 to 5 of each subsequent 28-day cycle, if the first cycle was well tolerated; Concomitant TMZ = concomitant temozolomide, 75 mg/m2/ day for 42 days with radiotherapy; PCV = lomustine (CCNU), 110 mg/m2, on day 1; procarbazine, 60 mg/m2 on days 8 to 21; vincristine, 1,5 mg/m2 (maximum dose, 2 mg), on days 8 and 29; WHO = World Health Organization |
| Anaplastic oligodendroglioma and anaplastic oligoastrocytoma (WHO grade III) | Maximal surgical resection, with the following options after surgery (no accepted standard treatment): radiotherapy alone, TMZ or PCV with or without radiotherapy afterward, radiotherapy plus concomitant and adjuvant TMZ, or radiotherapy plus adjuvant TMZ Radiotherapy is administered at a dose of 60 Gy given in 30 fractions over a period of 6 weeks. ; Adjuvant TMZ = adjuvant temozolomide, beginning 4 weeks after radiotherapy, 150 mg/m2/day on days 1 to 5 of the first 28-day cycle, followed by 200 mg/m2/day on days 1 to 5 of each subsequent 28-day cycle, if the first cycle was well tolerated; Concomitant TMZ = concomitant temozolomide, 75 mg/m2/ day for 42 days with radiotherapy; PCV = lomustine (CCNU), 110 mg/m2, on day 1; procarbazine, 60 mg/m2 on days 8 to 21; vincristine, 1,5 mg/m2 (maximum dose, 2 mg), on days 8 and 29; WHO = World Health Organization |
| Recurrent tumours | Reoperation in selected patients, conventional chemotherapy (e.g., lomustine, carmustine, PCV, carboplatin, irinotecan, etoposide), bevacizumab plus irinotecan, experimental therapies + |
In patients with malignant gliomas, treated with temozolomide and RT, have been described with sub-acute treatment-related reactions with or without clinical deterioration, showing oedema and sometimes contrast enhancement on MRI, suggestive of tumour progression.51-53 The occurrence of pseudo progression is mostly within the first 2 months after temozolomide ChT-RT.
In a prospective phase III trials with RT only, pseudo progression occurred in three of 32 (9%) patients.54 More recent study on 85 patients with malignant gliomas treated with temozolomide ChT-RT, pseudo progression occurred in 18 (21%) patients.55 In one third of patients treated with temozolomide ChT-RT, the increase in radiological abnormalities was accompanied by new focal signs, but in most patients the increase in radiological abnormalities was clinically asymptomatic.55 In the study involving 103 patients, pseudo progression was noted in 32 patients (31%), and was clinically symptomatic in 11 (34%) of these patients. Patients with MGMT have more frequent pseudo progression and it was connected with better overall survival.56
Most likely, pseudo progression is induced by a pronounced local tissue reaction with an inflammatory component, oedema, and abnormal vessel permeability causing new or increased contrast enhancement on neuroimaging. In less severe cases, this event can subside without the further treatment, but in more severe cases it can result, over time, in true treatment-related necrosis.
The possibilities of a good functional outcome in patients with malignant gliomas could be increased with good early medical rehabilitation treatment.57
For glioblastoma, median time to progression after the treatment with RT and temozolomide is 6.9 months.36 In case of symptomatic disease from mass effect, reoperation may be indicated (Table 4), with limited prolongation of survival afterwards.58
The treatment of recurrent malignant gliomas with RT is controversial. Some data have suggested that fractionated stereotactic reirradiation (SRT) and stereotactic radiosurgery (SRS) may be beneficial.59 Observational series of patients with recurrent malignant gliomas, treated with SRT showed the median survival of 12 months for patients with grade III tumours and eight months for those with grade IV lesions.60 The one-year survival rates were 65% and 23 % for patients with grade III and IV lesions, respectively. Kong DS
The conventional ChT is more effective for anaplastic gliomas than for glioblastomas. In general, the conventional ChT has modest value for recurrent malignant gliomas. There is no established ChT regimen available and patients are best treated within investigational clinical protocols. Temozolomide was evaluated in a phase II study in patients with recurrent anaplastic gliomas who had previously been treated with nitrosoureas.62 The response rate was 35%, and the 6-month rate of progression-free survival was 46%, comparing favourably with the 31% rate of progression-free survival at 6 months for therapies that were reported to be ineffective.63 In patients with recurrent glioblastomas, temozolomide has only limited activity, with response rate of 5.4% and 6-month rate of progression-free survival of 21%.64 Different temozolomide doses and administration regimens have been developed. With the aim of depleting MGMT, Brock
Other chemotherapeutic agents that are used for recurrent gliomas include nitrosoureas, carboplatin, procarbazine, irinotecan, and etoposide. Nitrosoureas (carmustine, fotemustine) either as single agents or in combination regimens as procarbazine, lomustine and vincristine (PCV) have shown activity in phase II studies in previously treated patients. Brandes
As combination regiment PCV, Schmidt F
Bevacizumab is a monoclonal antibody, which binds to vascular endothelial growth factor (VEGF), the key driver of neovascularization, and thereby inhibits the binding of VEGF to its receptors, VEGFR-1 and VEGFR-2, on the surface of endothelial cells. It demonstrated significant clinical activity in phase II studies using bevacizumab as a single agent or in combination with ChT agents such as irinotecan for patients with grade 3 and grade 4 malignant gliomas (higher objective response, progression-free survival and overall survival) in recurrent glioblastomas72-74 and has been approved by Food and Drug Administration (FDA) for the secondary treatment of glioblastoma in USA75, but it is not approved yet by European Medicines Agency (EMA).76
The most extensive experience with bevacizumab comes from a noncomparative phase II trial, in which 167 patients with recurrent glioblastomas, priory treated with ChT with temozolomide, were randomly assigned to bevacizumab, either as a single agent or at the same dose in conjunction with irinotecan.73 Treatment cycles were repeated every two weeks. The objective response rates with bevacizumab alone or in combination with irinotecan were 28% and 38%, respectively, and the six-month progression-free survival rates and overall survival were 43% and 50 %, and 9.2 and 8.7 months, respectively. An update of the results was presented at the 2010 American Society of Clinical Oncology (ASCO) meeting.74 Overall safety and efficacy were similar to that previously presented; the 12 and 24-month survival rates were 38% and 16% to 17% on both treatment arms, which appear to be better than historical control series.
According to our experience, at Institute of Oncology Ljubljana, we treated 19 patients with recurrent malignant gliomas with bevacizumab and irinotecan, from August 2008 to November 2011. The objective response rates were 47.4 % and 10.5% after 3 and 6 months respectively. The six-month time to progression interval rate and overall survival were 52.6% and 68.4% and 6.8 and 7.7 months, respectively (Figure 1).77
Bevacizumab alone or in combination with ChT has not been demonstrated to prolong the overall survival. Pivotal studies to determine the impact of this agent on overall survival are ongoing.
According to the Central Brain Tumor Registry of United States of America (CBTRUS), in one series of over 14,000 cases, 44% of cases were patients aged 65 years or more.78 Older age and poor performance status are associated with shorter survival.
RT among patients older than 70 years has a modest benefit in the median survival (29.1 weeks) as compared with supportive care (16.9 weeks).79 Older patients tolerate therapy less well than younger patients, so the treatment regimen should be adjusted. RT applied as abbreviated course (40 Gy in 15 fractions over a period of 3 weeks) or temozolomide as monotherapy has similar outcomes as conventional RT regimens.80,81
Two contemporary randomized trials conducted exclusively in older patients have new data about the optimal treatment approach. Both trials, Methusalem trial (NOA-08)78 and Nordic Elderly Trial82 have compared initial ChT as monotherapy with RT alone. In the Methusalem Trial the median age was 72 years.78 Patients treated with RT has a better survival, the median survival was 293 vs. 245 days, one year survival was 38% vs. 31%, the toxicity was more severe in patients treated with CTh. In Nordic Elderly Trial the median age was 70 years. Patients were treated with RT 60 Gy (6 weeks), 34 Gy (6 weeks) and temozolomide as monotherapy. In this trial patients treated with CTh had a better survival, with the overall survival of 6, 7.5 and 8.3 months, respectively. It seems that there might be benefit from systemic treatment over RT in patients with MGMT methylated tumours.
Increased understanding of the molecular pathways involved in signal transduction, angiogenesis and cell growth has led to the development of a number of targeted agents, which are now under active evaluation, alone and in various combinations for patients with malignant gliomas and other tumours. Other investigational therapies for malignant gliomas include chemotherapeutic agents that cross the blood-tumour barrier more effectively, gene therapy, peptide and dendritic-cell vaccines, radiolabeled monoclonal antibodies against the extracellular matrix protein tenascin, synthetic chlorotoxins (131I-TM-601), and infusion of radiolabeled drugs and targeted toxins into the tumour and surrounding brain by means of convection-enhanced delivery. Promising investigational therapies are selected in Table 5.28
Selected investigational therapies for malignant gliomas Additional data are from Sathorsumetee
| Type of treatment | Example |
|---|---|
| Convection enhanced surgical delivery of pharmacologic agent | Cintredekin besudotox |
| Drugs to overcome resistance to TMZ | |
| Dose dense TMZ | O6-benzylguanine |
| MGMT inhibitors | BSI-201, ABT-888 |
| PARP inhibitors | RTA 744, ANG 1005 |
| New chemotherapies | |
| Antiangiogenic therapies | |
| Anti-avb5 integrins | Cilengitide |
| Anti-hepatocyte growth factor | AMG-102 |
| Anti-VEGF | Bevacizumab, aflibercept (VEGF-trap) |
| Anti-VEGFR | Cediranib, pazopanib, sorafenib, sunitinib, vandetinib, vatalanib, XLI 84, CT-322 |
| Other agents | Thalidomide |
| Targeted molecular therapies | |
| Akt | Perifosine |
| EGFR inhibitors | Erlotinib, gefitinib, lapatinib, BIBW2992, nimotuzumab, cetuximab |
| FTI inhibitors | Tipifarnib, lonafanib |
| HDAC inhibitors | Vorinostat, depsipeptide, LBH589 |
| HSP90 inhibitors | ATI3387 |
| Met | XLI84 |
| mTOR inhibitors | Everolimus, sirolimus, temsirolimus, deforolimus |
| PI3K inhibitors | BEZ235, XL765 |
| PKCb | Enzastaurin |
| PDGFR | inhibitors Dasatinib, imatinib, tandutinib |
| Proteasome | Bortezomib |
| Raf | Sorafenib |
| Src | Dasatinib |
| TGF | b API2009 |
| Combination therapies | Erlotinib plus temsirolimus, gefitinib plus everolimus, gefitinib plus sirolimus, saorafenib plus temsirolimus, erlotinib, or tipifarnib, pazopanib plus lapatinib |
| Immunotherapies | |
| Dendritic cell and EGFRvIII peptide vaccines | DCVax, CDX-110 |
| Monoclonal antibodies | 131I-anti-tenascin antibody |
| Gene therapy | |
| Other therapies | 131I-TM-601 |
Malignant gliomas remains difficult to treat, and despite the efforts to improve the treatment outcome, the survival of patients with malignant gliomas is poor, with median survival of slightly above one year.
After revolutionary change in the postoperative setting with RT-ChT with Temozolomide has been achieved, mostly negative trials follow. AVAGLIO and RTOG 0825 trials were negative. Even though the AVAGLIO trial kind of suggests progression-free survival and QOL improvement, these are not clear cut results and upon review the actual pro-gression-free survival benefit was smaller, while QOL results are completely contradictory. In the recurrent malignant glioma setting, still nothing significant has been achieved.
The optimal management requires a multidisciplinary approach and knowledge of potential complications from both the disease and its treatment. In the future, with the better understanding of the molecular pathogenesis of malignant gliomas, it may be possible to select the most appropriate therapies on the basis of the patient’s tumour genotype and in that way more effective therapies can be developed for malignant gliomas. Most of all, further targeted therapy approaches should be biomarker driven.